Undercut the original and flood the market
When a blockbuster patent expires, the architecture of access shifts — not just for shareholders, but for the millions who could never afford the original price. Brazil's health regulator Anvisa has approved Ozivy, the first generic version of Ozempic, clearing the way for EMS to bring semaglutide to a far broader population at 30 percent below the brand-name cost. The moment marks less a corporate milestone than a quiet renegotiation of who gets to participate in one of medicine's most consequential recent advances.
- The patent wall around Ozempic fell on March 20, and EMS moved fast — Ozivy is now the first generic semaglutide to clear Anvisa, with five more products still queued behind it.
- Half a billion reais in projected first-year sales signals just how compressed and competitive this market is about to become, with generics threatening to redraw the entire GLP-1 landscape in Brazil.
- EMS is not just undercutting Novo Nordisk on price — it is offering pharmacies double the margin, a calculated move to win the shelf space and sales-floor loyalty that determines which pill a customer actually walks out with.
- Eurofarma chose a different battlefield entirely, licensing the original molecule from Novo Nordisk and selling it under new brand names for as little as R$300 a month — proof that the race for market share is being run on multiple tracks at once.
- Pharmacy chains like RD Saúde and Pague Menos stand to gain from both volume and margin as cheaper alternatives multiply, suggesting the disruption will ripple well beyond the manufacturers themselves.
Brazil's drug regulator Anvisa approved Ozivy today — a synthetic copy of Ozempic developed by pharmaceutical company EMS — marking the first generic version of Novo Nordisk's blockbuster diabetes and weight-loss drug to reach the Brazilian market since its patent expired in late March. Five additional synthetic versions and one biologic alternative remain under regulatory review.
Ozivy's initial approval covers only type 2 diabetes treatment. It should reach pharmacy shelves within one to two months, pending a price ceiling from Brazil's cost regulator. EMS projects the drug will generate more than R$500 million in its first year — roughly 5 percent of the company's total revenue — making it the firm's top-selling product almost immediately.
The commercial logic is aggressive: price Ozivy at least 30 percent below Ozempic and offer pharmacies roughly double the margin they currently earn on the original brand. That second move matters as much as the first. Pharmacy chains hold real influence over which products get recommended and displayed, and EMS is clearly courting that power.
Analysts at Santander noted that Ozivy's approval could accelerate the regulatory path for competing semaglutide products, with Hypera among the companies likely to win early clearance. For pharmacy chains like RD Saúde and Pague Menos, the proliferation of cheaper alternatives promises higher volumes in a category that already carries strong structural margins.
Not every competitor is following the generic playbook. Eurofarma struck a licensing deal with Novo Nordisk itself, distributing the original molecule under different brand names — Extensior and Poviztra — at significantly lower prices. Through its EuroCuida program, monthly treatment runs between R$300 and R$600, less than half the cost of branded Ozempic. The diverging strategies raise a question that will take years to answer: whether generic copies, licensed alternatives, or some hybrid approach will ultimately determine how — and how widely — Brazilians gain access to these drugs.
Brazil's drug regulator gave the green light today to Ozivy, a synthetic copy of Ozempic made by the pharmaceutical company EMS. The approval marks a turning point in the market for weight-loss and diabetes medications—the first time Anvisa has cleared a generic version of Novo Nordisk's blockbuster drug since its patent expired on March 20. Five more synthetic versions and one biologic alternative are still waiting in the regulatory queue.
Ozivy received initial approval only for type 2 diabetes treatment. The drug should reach pharmacy shelves within the next month or two, once Brazil's price regulator sets a ceiling on what it can cost. For EMS, the stakes are substantial. The company projects the medication will bring in more than half a billion reais in its first year—enough to account for 5 percent of the firm's total revenue and instantly become its bestselling product by sales volume.
The strategy is straightforward: undercut the original and flood the market. EMS will price Ozivy at least 30 percent below Ozempic, a gap designed to pull customers away from the brand name. But the company is also thinking about the pharmacies themselves. While Ozempic leaves retailers with roughly 15 percent profit margin, EMS signaled it would offer double that as competition heats up. That sweetener matters. Pharmacy chains have real power in deciding which products get shelf space and customer attention.
Analysts see the approval as a catalyst. At Santander, economist Caio Moscardin wrote that Ozivy's clearance could smooth the path for the other semaglutide products waiting at Anvisa. Hypera, another Brazilian drugmaker, stands a good chance of being among the first three companies to win approval, he noted. For pharmacy chains like RD Saúde and Pague Menos, the news is welcome—cheaper alternatives to Ozempic should drive volume, and the category already carries structurally higher margins than most medications.
Not everyone is chasing the generic route. Eurofarma took a different path, striking a deal with Novo Nordisk itself to distribute the original drug under different brand names with separate pricing and marketing strategies. Its Extensior and Poviztra versions are already in stores, priced significantly lower than the original Ozempic. Through a program called EuroCuida, Eurofarma offers monthly treatment for 300 to 600 reais—less than half the thousand-real price tag on the original brand. It's a reminder that there are multiple ways to compete in a market suddenly flooded with options. The real question now is which approach—generic copies, licensed alternatives, or some combination—will ultimately reshape how Brazilians access these drugs.
Notable Quotes
The approval of Ozivy could pave the way for additional approvals of other semaglutide products at Anvisa, with Hypera positioned to be among the first three companies to receive regulatory clearance.— Caio Moscardin, Santander analyst
The Hearth Conversation Another angle on the story
Why does it matter that EMS got here first with a generic version?
Because they're setting the template. They're not just undercutting price—they're restructuring how pharmacies make money on this category. That changes which products get recommended, which shelves they sit on.
The patent expiration in March—was that the only thing holding back generics?
Legally, yes. But there's also the regulatory approval process itself. Anvisa had to verify that EMS's synthetic version actually works the same way. That took time. Now that one is approved, the others in the pipeline have a clearer path.
Why would Eurofarma partner with Novo Nordisk instead of making its own generic?
Different risk calculation. They get the certainty of the original formula and Novo's backing, but they control distribution and pricing. They're not betting on their own manufacturing capability the way EMS is.
Does the pharmacy margin really drive which drug gets sold?
It's one factor among several. Doctors prescribe based on efficacy and patient need. But when two drugs are equivalent, the margin matters to the pharmacist's recommendation, and it matters to inventory decisions.
What happens to Novo Nordisk's market share in Brazil?
It shrinks. But they're not disappearing. They still have brand recognition, doctor relationships, and patients who trust the original. They're just no longer the only option.